SVBI — Interim / Quarterly Report 2019

Nov 22, 2019

Inventor Conference 2018

==> picture [313 x 106] intentionally omitted <==

科妍生物科技股份有限公司 SciVision Biotech Inc.

Dr. Chun Chang Chen Project Manager | R&D Dept

==> picture [66 x 17] intentionally omitted <==

This slide contains our business prospect, financial condition and sales which are derived from our prognosis existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forward-looking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control. The forward-looking statement in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.

==> picture [60 x 13] intentionally omitted <==

1. Company & Product &Technology Overview

2. Business Operation

==> picture [60 x 13] intentionally omitted <==

 Established in 2001

 Listed on TSE in 2013 (Code: 1786)

• Located in Kaohsiung Export Processing Zone, Taiwan

• Professional in Hyaluronic Acid medical device production

 Factory covers an area of 19,781.85 ㎡(5,984 Taiwanese ping)

• Follow to ISO 13485, GMP, US FDA and PIC/s GMP standards

• Produces 12 million syringes of medical device annually

==> picture [182 x 137] intentionally omitted <==

==> picture [180 x 55] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Drug delivery Dermal Synovial Fluid AntiFiller Supplement adhesion

C H A P (Crosslinked Hyaluronic Acid Platform)

Hyaluronic Acid

Hyaluronic Acid

Hyaluronic Acid

==> picture [60 x 13] intentionally omitted <==

Hyaluronic Acid

	Strong worldwide IPR	Strong worldwide IPR	Strong worldwide IPR	Strong worldwide IPR	Strong worldwide IPR	Strong worldwide IPR	for CHAP	for CHAP	for CHAP
	United States				Taiwan				Japan
			China				Europe

Important strategic partner

==> picture [158 x 72] intentionally omitted <==

==> picture [146 x 146] intentionally omitted <==

==> picture [146 x 68] intentionally omitted <==

==> picture [171 x 61] intentionally omitted <==

==> picture [161 x 112] intentionally omitted <==

==> picture [185 x 67] intentionally omitted <==

==> picture [140 x 66] intentionally omitted <==

==> picture [146 x 60] intentionally omitted <==

==> picture [177 x 56] intentionally omitted <==

==> picture [138 x 42] intentionally omitted <==

==> picture [215 x 69] intentionally omitted <==

==> picture [140 x 57] intentionally omitted <==

==> picture [110 x 65] intentionally omitted <==

==> picture [143 x 57] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Application field	Items	Global market value in 2018	CAGR
Facial Aesthetics	Dermal Filler	1.6 billion	9.0 %
Geriatrics care	Viscosupplement	2.1 billion	6.1 %
Surgery	Adhesion Barrier	2.8 billion	8.9 %

source :

1. Facial Aesthetics (Botulinum Toxin, Dermal Fillers), GlobalData

2. Hyaluronic Acid Viscosupplementation | Medtech 360 | Market Analysis | Global | 2019 , DRG

3. ANTI-ADHESION PRODUCTS 2012, Global Industry Analysts, Inc.

==> picture [60 x 13] intentionally omitted <==

Restore youth and beauty

==> picture [594 x 266] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

https://technews.tw/2016/12/31/scientists-mayhave-identified-the-protein-that-controls-aging/

Hyaluronic acid dermal filler is the market's highest microplastic product

==> picture [682 x 319] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Hyaluronic acid Dermal Filler can be divided Monophasic Fillers (Smooth gel ) and Biphasic Fillers (Particle type) according to the colloidal form of the product. The products represented by each are Juererm of Allergan and Restylane of Galderma.

Allergan's Juvederm and Galderma's Restylane are also the two leading products in the hyaluronic acid Dermal Filler market.

==> picture [176 x 160] intentionally omitted <==

==> picture [182 x 160] intentionally omitted <==

Monophasic Fillers (Smooth gel ) – Allergan Juvederm

Biphasic Fillers (Particle type) – Galderma Restylane

==> picture [60 x 13] intentionally omitted <==

==> picture [241 x 333] intentionally omitted <==

==> picture [350 x 217] intentionally omitted <==

Monophasic Fillers (Smooth gel ) Biphasic Fillers (Particle type)

==> picture [60 x 13] intentionally omitted <==

ANIMERS (smooth gel) Advantage  High security  Smooth and natural  Easy operation

==> picture [272 x 377] intentionally omitted <==

Monophasic Fillers (Smooth gel )

==> picture [60 x 13] intentionally omitted <==

ANIMERS (smooth gel)

Advantage  High security  Smooth and natural  Easy operation

Before

After

==> picture [126 x 156] intentionally omitted <==

==> picture [124 x 158] intentionally omitted <==

==> picture [386 x 158] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

==> picture [142 x 250] intentionally omitted <==

HYADERMIS/ FACILLE (Particle type)

Advantage

 High safety performance  Strong structural support  Shift resistance

==> picture [269 x 168] intentionally omitted <==

• Lasting effect

==> picture [60 x 13] intentionally omitted <==

Strong structural support

==> picture [359 x 178] intentionally omitted <==

Shift resistance

==> picture [367 x 169] intentionally omitted <==

Beforec

After

==> picture [280 x 184] intentionally omitted <==

Beforec

After

==> picture [139 x 176] intentionally omitted <==

==> picture [139 x 181] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

==> picture [370 x 250] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

17

Journal of Cosmetics, Dermatological Sciences and Applications, 2016, 6, 1-8

==> picture [259 x 389] intentionally omitted <==

CHAP-HA has good usage satisfaction

==> picture [330 x 262] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

==> picture [273 x 371] intentionally omitted <==

CHAP-HA has good tissue compatibility

==> picture [364 x 356] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Osteoarthritis of the knee has been associated with a decrease in the elasticity and viscosity of the synovial fluid

==> picture [191 x 265] intentionally omitted <==

Inflammation (erythema and swelling) Lost of cartilage

==> picture [228 x 181] intentionally omitted <==

==> picture [146 x 17] intentionally omitted <==

----- Start of picture text -----

Nomal OA
----- End of picture text -----

==> picture [60 x 13] intentionally omitted <==

Advantage

3 INJECTION

 High Security Performance

 Long Lasting Effect

• High Comfort

• Needless of Excessive Injection

==> picture [60 x 13] intentionally omitted <==

Better than competing products Brand Artz HYAJOINT Synvisc Synvisc-One Durolane HYAJOINT Plus Manufacturing Seikagaku SciVision Genzyme Genzyme Q-Med AB SciVision HA raw material source Animal- derived Bacteria- derived Animal- derived Animal-derived Bacteria- derived Bacteria-derived HA Type Linear Linear Cross linked Cross linked Cross Linked Cross linked Gel Appearance smooth smooth smooth smooth grainyl smooth Linker None None DVS DVS BDDE BDDE Volume (ml/syringe) 2.5 3 2 6 3 3 HA con. (mg/ml) 10 10 8 8 20 20 Injection Types 5/3 3 3 1 1 1

JBJS America, impact factor=5.163 Top international journal in Orthopedics

==> picture [341 x 336] intentionally omitted <==

HYAJOINT Plus has a significantly better effect on relieving pain than competitive products

==> picture [212 x 143] intentionally omitted <==

==> picture [226 x 153] intentionally omitted <==

HYAJOINT Plus is significantly better than competitive products for more severe OA patients

==> picture [60 x 13] intentionally omitted <==

Journal of Back and Musculoskeletal Rehabilitation 31 (2018) 709–718

==> picture [269 x 386] intentionally omitted <==

The US thickness of the quadriceps and FIC improved signi fi cantly at both 3 and 6 months

==> picture [188 x 120] intentionally omitted <==

Measurement of quadriceps thickness

==> picture [188 x 120] intentionally omitted <==

Measurement of femoral intercondylar cartilage thickness

==> picture [60 x 13] intentionally omitted <==

Injured organ or tissue

==> picture [46 x 51] intentionally omitted <==

The fibrin acts like a glue to seal the injury

Adhesion formation

Inflammation

==> picture [262 x 197] intentionally omitted <==

Gynecologic surgery

==> picture [262 x 198] intentionally omitted <==

Tendon, peripheral nerve, joint surgery

==> picture [60 x 13] intentionally omitted <==

Absorbable Adhesion Barrier Gynecologic surgery

==> picture [308 x 242] intentionally omitted <==

Absorbable Adhesion Barrier Tendon, peripheral nerve, joint surgery

==> picture [360 x 351] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Absorbable Adhesion Barrier Gynecologic surgery

PROTAHERE

Advantage  High Biocompatibility  Easy to apply

==> picture [343 x 290] intentionally omitted <==

• Shift resistance

==> picture [60 x 13] intentionally omitted <==

Products Items Preclude SurgiWarp Interceed Seprafilm Hyalobarrier PROTAHERE Company GORE MAST BIOSURGERY Johnson SANOFI Fidia SCIVISION Material expanded polytetrafluo roethylene (ePTFE) Polylactic Acid (PLA) oxidized regenerated cellulose (ORC) Hyaluronic Acid and Carboxymet hyl cellulose (CMC) Cross-linked Hyaluronic Acid Cross-linked Hyaluronic Acid Type Film Film Film Film gel gel Absorbability Non ☼ ☼☼ ☼☼☼ ☼☼☼☼ ☼☼☼☼ Usability ☼ ☼☼ ☼☼ ☼☼☼ ☼☼☼☼ ☼☼☼☼ Shift resistance ☼ ☼ ☼☼ ☼☼ ☼☼☼ ☼☼☼☼ Better than competing products

Control group (Unused) Use PROTAHERE

==> picture [337 x 218] intentionally omitted <==

==> picture [330 x 218] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Absorbable Adhesion Barrier Tendon, peripheral nerve, joint surgery

DEFEHERE Advantage

• High Biocompatibility

• Easy to apply

• High viscosity

• Long effective protection time

==> picture [60 x 13] intentionally omitted <==

Product Item OrthoWrap FzioMed Hyaloglide DEFEHERE Company Mast Medtronic Anika SCIVISION Material Polylactic Acid (PLA) Polyethylene oxide(PEO) and carboxymethylcell ulose (CMC) Cross-linked Hyaluronic Acid Cross-linked Hyaluronic Acid Type Film gel gel gel Usability ☼ (Suture in place) ☼☼☼☼ ☼☼☼☼ ☼☼☼☼ Biocompatibility ☼☼☼ ☼☼ ☼☼☼☼ ☼☼☼☼ Anti-degradation ability - - ☼☼ ☼☼☼ Better than competing products

1. Company & Product &Technology Overview

2. Business Operation

==> picture [60 x 13] intentionally omitted <==

Profit & Loss-Consolidated

==> picture [670 x 381] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

2019 Jan.~Sep. & 2018 Jan.~Sep.

==> picture [544 x 386] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

2019 Jan.~Sep. & 2018 Jan.~Sep.

==> picture [566 x 384] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Balance Sheet-Consolidated

==> picture [626 x 404] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Cash Flows-Consolidated

==> picture [622 x 421] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Revenue

==> picture [345 x 155] intentionally omitted <==

Net Profit

==> picture [348 x 201] intentionally omitted <==

Gross and Operating Margin

==> picture [351 x 155] intentionally omitted <==

Cash Generated From Operations Before Interest And Taxes

==> picture [350 x 202] intentionally omitted <==

==> picture [60 x 13] intentionally omitted <==

Science Creates Better Visions

==> picture [60 x 13] intentionally omitted <==